Kornimate/medical-research-clean huggingface dataset:
community-based delivery of integrated family planning/hiv testing and counseling services in uganda

Conditions: HIV Testing and Counseling

Summary: the purpose of this study is to evaluate the feasibility and acceptability of adding hiv testing and counseling (htc) services to the family planning (fp) services provided by community health workers in uganda.

the uganda ministry of health is implementing a village health team strategy whereby lay volunteers, called vhts, provide a government-endorsed platform for all community-based health programming. where trained, vhts already offered family planning services, including injectable contraceptives. in this project, vhts already providing family planning services are trained to offer hiv testing and counseling services (htc). the goal is to reach individuals whose sexual and reproductive health needs may be underserved by clinic-based services, while also attempting to mitigate some of the barriers to htc like access and stigma. the study uses a two-arm post-test only randomized cluster design, with eight pair-matched health centers in two districts randomly assigned to intervention or control arm. vhts supported by health centers in the intervention arm receive classroom training and supervised practical experience in htc. supervision and commodity supply occur through health centers, building on support mechanisms for family planning. external quality assurance is conducted quarterly through health centers as part of program implementation. vhts receive refresher training after 8 months. vhts in the intervention arm provide both family planning and htc services during the study period, and then return to providing family planning only at the end of the project. vhts in the control arm only provide family planning. htc and/or family planning services, as applicable, are available to all adults in the communities served by the vhts.

Eligibility criteria:
inclusion criteria: * at least six months of experience providing family planning services, including injectable contraceptives * attached to one of the eight health centers selected for the study for supervision, commodity supply, and referral management * all vhts in the intervention group are trained in htc service provision and interviewed as part of the evaluation. vhts in the control group are not interviewed. services (family planning and/or htc) are made available to all adults in vhts' communities. data collection involves a client survey. inclusion criteria for participation in the survey are: * age 18 or more * female * revisit family planning clients of vhts (will have received family planning services from the vht more than once) * where this service is available, having received htc from the vht is not an eligibility criterion exclusion criteria: * n/a
the clinical efficacy of drug sensitive neoadjuvant chemotherapy based on organoid versus traditional neoadjuvant chemotherapy in advanced gastric cancer

Conditions: Advanced Gastric Carcinoma

Summary: neoadjuvant chemotherapy has become the mainstream recommended treatment for advanced gastric cancer. however, due to the heterogeneity of gastric cancer, part of some patients fail to benefit from the treatment. this project aims to compare the clinical efficacy of individualized neoadjuvant therapy based on patient-derived organoid drug sensitivity assay and traditional regimen, exploring the advantages and disadvantages of these two treatments. and access the safety and clinical value of the personalized neoadjuvant therapy based on patient-derived organoid drug sensitivity assay in advanced gastric cancer.


Eligibility criteria:
inclusion criteria: * age between 18 and 80 years * a biopsy proven histological diagnosis of gastric adenocarcinoma or high-grade intraepithelial neoplasia * tumor located at stomach * chest/abdomen/pelvis ct scans or gastric cancer staging ct scan evaluate the clinical stage of tumor as stage iii: a. preoperative staging ct3-4n1-2 b. excluding distant organ metastasis (m0) * eastern cooperative oncology group (ecog) score ≤1 * willing to participate and informed consent signed exclusion criteria: * pregnant or lactating women * synchronous or heterochronic malignant carcinomas * history of malignant carcinomas * clinical evidence of metastasis * abnormal heart, lung, liver, kidney, hematopoietic function and bone marrow reserve function, unable to tolerate surgical treatment and chemotherapy * mental illness or other serious cardiovascular disease * emergency procedure

Keywords: advanced gastric carcinoma patient-derived organoid personalized treatment neoadjuvant chemotherapy
comparison on the efficacy of a monophasic

Conditions: Cardiac Arrest

Summary: the central purpose of this study is to compare the clinical outcomes of patients who suffered a cardiac arrest while hospitalized at the va and were resuscitated after biphasic defibrillators were implemented in 2001 to clinical outcomes of patients who suffered cardiac arrest before 2001.

the central purpose of this study is to compare the clinical outcomes of patients who suffered a cardiac arrest while hospitalized at the va and were resuscitated after biphasic defibrillators were implemented in 2001 to clinical outcomes of patients who suffered cardiac arrest before 2001. this study will retrospectively collect and analyze clinical data related to the atlanta va medical center, a member of the national registry of cardiopulmonary resuscitation, to assess clinical parameters in cardiac arrest survivors. this study focuses on collecting data retrospectively in regard to cardiac arrest patients to discern what factors are playing a role in patient survival after cardiac arrest. such data will help hospitals and physicians to improve quality of care in patients at risk for cardiac arrest as well as to implement strategies to reduce such events or improve management of these high-risk patients in order to save lives.

Eligibility criteria:
inclusion criteria: * clinical outcomes of patients who suffered a cardiac arrest while hospitalized and were resuscitated after biphasic defibrillators were implemented in 2001 to clinical outcomes of patients who suffered cardiac arrest before 2001. exclusion criteria: biphasic defibrillators were implemented cardiac arrest before 2001

Keywords: cardiac arrest biphasic defibrillator
phase iib 2-period crossover polysomnography study in participants with primary insomnia (mk-4305-006)

Conditions: Primary Insomnia

Summary: a cross-over, polysomnography study to test the safety, tolerability and effectiveness of different doses of suvorexant (mk-4305) in the treatment of patients with primary insomnia.


Eligibility criteria:
inclusion criteria: * has a diagnosis of primary insomnia based on sleep history and the investigator's judgment * must be willing to stay overnight at a sleep laboratory * must be willing to stay in bed for at least 8 hours each night while at the sleep laboratory * regular bedtime is between 9 pm and 12 am (midnight) exclusion criteria: * breast feeding, pregnant or planning to become pregnant during the study * within the past 6 months before starting the study you have a history of significant cardiovascular disorder such as unstable angina, congestive heart - failure or acute coronary syndrome * currently participating or have participated in a study with an investigational compound or device within the last 30 days * has traveled across 3 or more time zones in the last 2 weeks or plans on traveling across 3 or more time zones at any time during the study * has done shift work within the past 2 weeks * has donated blood products within the last 8 weeks * has difficulty sleeping due to a medical condition
flunarizine versus topiramate for chronic migraine prophylaxis

Conditions: Chronic Migraine

Summary: chronic migraine (cm) is a prevalent and devastating disorder with limited therapeutic options. this study explored the efficacy of 10 mg/day flunarizine for cm prophylaxis as compared with 50 mg/day topiramate.

chronic migraine (cm) is a prevalent and devastating disorder with limited therapeutic options. this study explored the efficacy of 10 mg/day flunarizine for cm prophylaxis as compared with 50 mg/day topiramate. we conducted a prospective, randomized, open-label, blinded-endpoint (probe) trial. patients with cm were randomized (1:1) to flunarizine and topiramate treatment groups. this study consisted of two periods: a prospective baseline screening period lasting up to 2 weeks (week -2 to week 0, t0), and a treatment period lasting 8 weeks after enrollment (weeks 0-8, t1-t4). the treatment phase consisted of a 2-week titration period (t1) and a 6-week maintenance period (t2-t4). during the titration period, subjects were given 25 mg/day topiramate or 5 mg/day flunarizine once daily in the first week, followed by 50 mg/day topiramate or 10 mg/day flunarizine in divided doses (twice daily) in the second week. when subjects could not tolerate this target dose, the initial dose was continued through t4. patients were followed per 2 weeks at the headache clinic. at each visit, diaries were collected and directed to the outcome evaluators, who were blinded to the patients' treatment. the primary outcomes assessed were the reductions in the total numbers of headache days and migraine days after 8 weeks of treatment (weeks 7 to 8 vs. weeks -2 to 0). secondary outcomes were reductions in the numbers of days of acute abortive medication intake and acute abortive medication tablets taken, and the 50% responder rate.

Eligibility criteria:
inclusion criteria: * ichd-iir criteria for cm (as reported by the patient) * experienced ≥7 days of headache lasting ≥30 min during t0 (-2 week to 0 week). * on ≥4 of these days, subjects were required to have experienced migrainous headache * prophylaxis-naïve (i.e., patients could not receive any preventive medications) * with and without medication overuse exclusion criteria: * headache type other than cm * migraine onset after the age of 50 years * cm onset after the age of 60 years * previous history of migraine prophylaxis before enrollment * pregnancy or nursing status * history of hepatic or renal disorder, nephrolithiasis or other severe systemic disease * severe depression (bdi score ≥ 30 at visit 1) * conditions incompatible with mri, such as claustrophobia or metallic or electric implants

Keywords: chronic migraine prophylaxis flunarizine topiramate
volume vs concentration: quadratus lumborum blocks with high volume/low concentration or low volume/ high concentration in nephrectomies

Conditions: Analgesia; Postoperative Pain; Block

Summary: the quadratus lumborum has since 2016 become standard of care for abdominal and retroperitoneal surgeries at upmc-shadyside hospital, replacing paravertebral blocks, and as part of a broader multimodal analgesia institutional enhanced recovery after surgery protocol. since the first description of this technique, several approaches to and anatomic targets within the quadratus lumborum plane have been described although their mechanism of action, spread, and relative clinical effectiveness remain areas of some debate. what is proposed here is to investigate the relative clinical effectiveness of the relationship high volume/low concentration of local anesthetic or low volume/ high concentration of local anesthetic.


Eligibility criteria:
inclusion criteria: 1. patients 18-90 years old 2. patients undergoing nephrectomy 3. body mass index 19-36 4. male and female 5. all races 6. american society of anesthesiologist scale i, ii, iii exclusion criteria: 1. patient refusal 2. pregnancy 3. non-english speaking or inability to participate in the study 4. patients with coagulopathy or with international normalized ratio \>1,5 the day of the surgery. 5. chronic steroid use 6. chronic pain 7. chronic opiate use
surveillance for low and low-intermediate risk non-muscle invasive bladder cancer: a pilot study

Conditions: Bladder Cancer

Summary: this is a two-arm, randomized-controlled pilot study with 2 year duration. the "intervention" refers to surveillance based on the european association of urology (eau) guidelines and the "control" refers to surveillance based on the american urological association (aua) guidelines.

this is a two-arm, randomized-controlled pilot study with 2 year duration. the "intervention" refers to surveillance based on the eau guidelines and the "control" refers to surveillance based on the aua guidelines. research methods: participants who presents with non-muscle invasive bladder cancer and meets the inclusion/exclusion criteria will be given an option to participate in the study. participants will be enrolled at the urology clinics at the university of texas health science center san antonio (uthscsa) medical arts and research center (marc) and south texas veterans health care system (stvhcs). non-local site include the university of texas southwestern medical center (utsw). the research procedures consist of urine collection, cystoscopy, and patient satisfaction and cost questionnaires. the evaluation will be done by the tumor recurrence and progression of the disease. at various time points throughout the study, urine may be obtained from the patient and banked in the genitourinary (gu) tissue bank. subjects asked to provide a urine sample(s) will be asked to sign a separate informed consent. the urine is de-identified in the lab per the health insurance portability and accountability act (hipaa) protocol gu tissue bank institutional review board (irb) # 20050234h). patients will undergo cystoscopy in clinic (standard of care). in the intervention arm, patient surveillance cystoscopy will be performed at 3, 12 months and again at 24 months following the diagnosis of bladder cancer. patients randomized to the control arm, will undergo surveillance cystoscopy every 3 months for 2 years following the diagnosis of bladder cancer. because use of cytology is variable among the participating urologist, the utilization of cytology will be at the treating urologist's discretion as per usual standard care. study duration will be 2 years from most recent biopsy. patients will be placed on the surveillance schedule based on the length of time from their last tumor.

Eligibility criteria:
inclusion criteria: * must have non-muscle invasive low-grade, papillary (ta) bladder cancer. * must have a negative cystoscopy following most recent biopsy. * must be able to give informed consent. * must be age 18 or older. * must be at low- or low-intermediate risk for disease recurrence and progression according to the eau guidelines. exclusion criteria: * have a history of invasive (\>=t1) bladder cancer. * have a history of carcinoma-in-situ (cis). * unable to give informed consent. * \< 18 or younger. * variant histology (micropapillary, nested variant, non-urothelial cell carcinoma elements). * had a surveillance cystoscopy following most recent biopsy.
propofol pharmacokinetics and pharmacodynamics modelling

Conditions: Intravenous Anesthetic Agent Overdose

Summary: the main purpose of this research is to develop a population pharmacokinetic and pharmacodynamic model of propofol when used for induction and maintenance of anaesthesia, using bis as a pharmacodynamic endpoint. a covariate analysis will be performed in order to account for variability in pharmacokinetic and pharmacodynamic parameters. the influence of age and obesity on propofol pharmacokinetic parameters will be particularly addressed.


Eligibility criteria:
inclusion criteria: * adult patients admitted for nose or ear surgery, bariatric surgery or urgent orthopaedic surgery. exclusion criteria: * severe hepatic or renal insufficiency; * significant haemodynamic instability previous to the surgery; * allergy to eggs or propofol at the time of enrolment; * predictive criteria for difficult airway management.

Keywords: anaesthetics intravenous propofol pharmacokinetics pharmacodynamics propofol pharmacokinetic-pharmacodynamic model
revealing engagement patterns among endometrial cancer patients

Conditions: Endometrial Cancer

Summary: the study intends to investigate the personal experiences of endometrial cancer patients who take part in a separate clinical study including a specific medication intervention. the major focus will be on closely following individuals' rates of trial completion and withdrawal. the data collected from this study will help improve future outcomes for all endometrial cancer patients as well as those in under-represented demographic groups.


Eligibility criteria:
inclusion criteria: * patients diagnosed with endometrial cancer * aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed * subjects willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examination. exclusion criteria: * refusal of consent * women of childbearing potential without a negative pregnancy test; or women who are lactating. * any serious and/or unstable pre-existing medical disorders

Keywords: endometrial cancer
flu shot pre-visit questionnaire

Conditions: Influenza

Summary: the purpose of this study is to assess, prospectively, the effect on flu vaccination rates of a pre-visit questionnaire that asks patients to indicate their preferences for a flu shot. responses to the questionnaire will also be shown to clinicians via additional text in an existing flu shot alert. the investigators hypothesize that the pre-visit questionnaire will lead to increased flu vaccination compared with standard practices.

the cdc (centers for disease control and prevention) recommends a flu vaccination to everyone aged 6+ months, with rare exception; almost anyone can benefit from the vaccine, which can reduce illnesses, missed work, hospitalizations, and death. one barrier to vaccination is a lack of "cues to action," which could be overcome by asking patients for a pre-visit commitment to get a flu shot and additional reminders for the clinician to act on this commitment. eligible patients will be randomized to either receive or not receive a one-item, pre-visit questionnaire about the flu shot (that will show responses to clinicians in an existing flu shot alert).

Eligibility criteria:
patient inclusion criteria: * on a list of active geisinger patients (all patients on this list attended at least one primary care appointment at geisinger between 10/1/2008 and 4/13/2022, and either had a geisinger primary care provider assigned as of april 2022, or were in the electronic health record \[ehr\] since at least september 2021 and had at least one encounter in 2020-2022) * has an upcoming flu shot-eligible outpatient visit with a provider * has activated geisinger's patient portal * has not yet received a flu vaccine at the time the questionnaire became available, according to the ehr clinician inclusion criteria * any geisinger clinician who sees patient-participants in our study for a flu shot-eligible outpatient visit

Keywords: vaccination health promotion health behavior reminder systems economics, behavioral
effect of dialysate temperature on haemodynamic stability and haemodialysis efficiency

Conditions: Acute Renal Failure; Chronic Renal Failure

Summary: comparison between dialysate temperatures on haemodynamic stability and haemodialysis efficiency.

comparison of 4 different dialysate temperatures for haemodialysis of patients with chronic renal failure. comparison of 3 different dialysate temperatures for haemodialysis of patients with acute renal failure. investigation of the efficiency of haemodialysis of patients with acute renal failure

Eligibility criteria:
inclusion criteria: * chronic renal failure * acute renal failure * aged between 21-90 years exclusion criteria: -
establish a national registry of rem sleep behavior disorder

Conditions: REM Sleep Behavior Disorder

Summary: in this proposed study, the investigators aim to build up a large cohort of rapid eye movement sleep behavior disorder (rbd) to study the etiology and risk factors of neurodegeneration.

rem sleep behavior disorder (rbd) is a parasomnia characterized by abnormal behavioral manifestations during rem sleep. accumulating evidence suggests that rbd is implicated as an integral part of disease progress of α-synucleinopathy neurodegeneration, such as parkinson's disease (pd) and dementia with lewy bodies.previous studies have identified a series of neurocognitive, autonomic, clinical and neurobiological markers for neurodegeneration in irbd, such as olfactory dysfunction, color vision deficit, autonomic dysfunction, tonic emg activity during rem sleep, and psychiatric disorder. however, the prevalence rate of rbd was relatively low and most of the rbd studies only have 100 or below cases. and there might be ethic differences in rbd which indicates that the findings from western countries might not be applicable to chinese. in these regards, the investigators aimed to build up a large cohort of rapid eye movement sleep behavior disorder (rbd) to study the etiology and risk factors of neurodegeneration.

Eligibility criteria:
inclusion criteria: case: according to the icsd-3 for the diagnosis of rbd 1. sleep talking or complex movement during sleep; 2. such movement was recorded by video psg (av-psg) during rem sleep or according to history the movements were occurred during rem; 3. rem sleep without atonia (rwa) during psg monitoring; 4. this abnormal phenomenon cannot be explained by other sleep disorder, psychiatric disease, drug or substance abuse. control: age and gender matched with consent 1. no rbd symptoms and psg characteristics; 2. no neurological symptoms or diseases, mri scan will be employed to exclude brain pathology; 3. no narcolepsy or hypersomnia, ruled out by multiple sleep latency test; 4. no history of mental illnesses or use of antidepressants. exclusion criteria: 1. subjects who refused to join the cohort.
to evaluate the effects of multiple doses of nilotinib on the pharmacokinetics and metabolism of midazolam in cml patients with additional extension phase to evaluate the safety of nilotinib

Conditions: Chronic Myeloid Leukemia

Summary: this study will evaluate the effects of multiple doses of nilotinib on the pharmacokinetics and metabolism of midazolam (as a sensitive cyp3a probe) in cml patients. the following extension study does evaluate the safety of nilotinib.


Eligibility criteria:
inclusion criteria: 1. patients with a cytopathologically confirmed diagnosis of ph+ cml or philadelphia chromosome- negative (ph-) cml patients in accelerated or chronic phase who are resistant and/or intolerant against at least one prior therapy with a bcr-abl tyrosine kinase inhibitor 2. female or male ≥ 18 years of age 3. patients who are nilotinib naïve at study entry, e.g. did not receive any nilotinib treatment prior to study 4. who performance status of ≤ 2 exclusion criteria: 1. known cytopathologically confirmed cns infiltration (in absence of suspicion of cns involvement, lumbar puncture not required). 2. impaired cardiac function 3. history of acute pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis. 4. patients actively receiving therapy with the prohibited co-medications (cyp3a4 inhibitors or inducers, or cyp2c inducers) 5. patients who are currently receiving treatment with any medications that have the potential to prolong the qt interval 6. treatment with immunotherapy or chemotherapy within 3 days (6 weeks for nitrosurea or mitomycin-c) prior to day 1 or who have not recovered from side effects of such therapy. 7. treatment with imatinib within 1 week prior to day 1 or who have not recovered from side effects of such therapy. 8. patients who have hypersensitivity to midazolam or related compounds other protocol-defined inclusion/exclusion criteria may apply

Keywords: cml, nilotinib, midazolam